

Supplementary material.

A population-based study on the incidence, risk factors and outcome of *Salmonella* bloodstream infections in South Sweden 2012-2022

Authors: Björklund L¹, Mattisson Y^{1,2}, Bläckberg A^{1,3}, Sunnerhagen T^{1,4} and Ljungquist O^{1,2}

Affiliations:

¹ *Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden*

² *Department of Infectious Diseases, Helsingborg hospital, Helsingborg, Sweden*

³ *Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden*

⁴ *Clinical Microbiology, Infection Prevention and Control, Office for Medical Services, Region Skåne, Lund, Sweden*

Corresponding author: Oskar Ljungquist. oskar.ljungquist@med.lu.se

Table A1. Antimicrobial resistance of *Salmonella* in bloodstream infections

Antibiotic	Proportions of resistant islets	No of isolates tested
Cefotaxim	4 (1%)	145
Ciprofloxacin	25 (17%)	144
Gentamicin	4 (3%)	115
Imipenem	0 (0%)	116
Meropenem	9 (8%)	109
Piperacillin-Tazobactam	0 (0%)	86
Tobramycin	0 (0%)	57
Trimethoprim-Sulfamethoxazole	7 (5%)	142
Azithromycin	0 (0%)	117